BACKGROUND In the RESOLUTE All Comers trial, the Resolute zotarolimus-eluting stent was non-inferior to the Xience V everolimus-eluting stent for the primary stent-related endpoint of target lesion failure (cardiac death, target vessel myocardial infarction, and ischaemia-driven target lesion revascularisation) at 1 year. However, data for long-term safety and efficacy from randomised studies o...

We thank Dr Paul D. Williams, Dr Mama A. Mamas, and Dr Douglas G. Fraser for their interest in our article. First, we investigated the stent fracture after Xience V (Abbott Vascular) and Promus (Boston Scientific). As they note, our results, therefore, do not apply to all everolimus-eluting stents. Second, they suggest that double stent strut layer shown in Figure 4 is the consequence of stent ...

BACKGROUND Fast post-implantation stent endothelialization is desirable for theoretically reducing the possibility of stent thrombosis. OBJECTIVE To evaluate the extent of sirolimus-eluting stent strut endothelialization (delivered from the luminal and abluminal aspects or abluminal aspect only) in the iliac arteries of rabbits. METHODS The iliac arteries of 10 rabbits were implanted with f...

Drug-eluting stents have proven long-term safety and effectiveness for the treatment of coronary artery disease especially due to their marked efficacy in reducing restenosis rates. Nevertheless, the rates of late and very late stent thrombosis, especially in first-generation systems, have raised some concerns. Moreover, percutaneous coronary intervention to small vessels (especially <2.5 mm) r...

To address concerns of late and very late stent thrombosis associated with first generation drug-eluting stent technology, novel approaches are being tested including stents with bioabsorbable polymers (including Biomatrix FlexTM, NoboriTM and SynergyTM), polymer-free drug delivery systems (including BiofreedomTM and Yukon®) and drug-eluting balloons (including Sequent PleaseTM, Dior® II and Pa...

BACKGROUND Our purpose was to investigate the clinical outcomes of Zotarolimus- and Paclitaxel-eluting stents in Turkish patients with coronary artery disease (CAD). In general, the outcome of drug-eluting stent (DES) placement has a proven efficacy in randomized trials. However, the difference in efficacy between the Zotarolimus and Paclitaxel-eluting stents in unselected Turkish patients is c...

AIMS The aim of this study was to investigate the physiologic parameters: fractional flow reserve (FFR), hyperaemic trans-stent gradient (HTG), and wall shear stress (WSS) at implantation and at 6-month follow-up in the drug-eluting sirolimus stent and in its bare metal counterpart implanted in pairs within the same patient. METHODS AND RESULTS Twenty patients, accepted for percutaneous coron...